Market revenue in 2023 | USD 270.1 million |
Market revenue in 2030 | USD 367.8 million |
Growth rate | 4.5% (CAGR from 2023 to 2030) |
Largest segment | Cuti |
Fastest growing segment | CDI |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | CUTI, CDI, ABSSSI, HABP, CABP, CIAI, BSI |
Key market players worldwide | Melinta Therapeutics, Basilea Pharmaceutica Ltd, Theravance Biopharma Inc, Seres Therapeutics Inc, AbbVie Inc, Merck & Co Inc, Hubsan, Wockhardt, Entasis Therapeutics, Tetraphase Pharmaceuticals, Paratek Pharmaceuticals, Axogen Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antibiotic resistance market will help companies and investors design strategic landscapes.
Cuti was the largest segment with a revenue share of 23.88% in 2023. Horizon Databook has segmented the Spain antibiotic resistance market based on cuti, cdi, absssi, habp, cabp, ciai, bsi covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain antibiotic resistance market , including forecasts for subscribers. This country databook contains high-level insights into Spain antibiotic resistance market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account